Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors

Amalya Sargsyan, Monika A Kucharczyk,Robin L Jones,Anastasia Constantinidou

Expert Review of Gastroenterology & Hepatology（2023）

引用 2|浏览10

暂无评分

摘要

Ripretinib is a safe and an effective therapy for the fourth-line setting in advanced/metastatic GIST. Future studies should evaluate combination schedules and the identification of markers predictive of benefit from ripretinib.

查看译文

关键词

Gastrointestinal stromal tumor,KIT,kinase inhibitor,mutations,resistance,ripretinib,systemic treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要